宣泰医药
(688247)
| 流通市值：15.40亿 | | | 总市值：49.05亿 |
| 流通股本：1.42亿 | | | 总股本：4.53亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 148,955,862.02 | 225,785,781.43 | 297,635,969.73 | 267,008,612.93 |
| 应收票据及应收账款 | 63,321,304.26 | 103,524,626.45 | 107,413,000.95 | 71,260,041.38 |
| 应收账款 | 63,321,304.26 | 103,524,626.45 | 107,413,000.95 | 71,260,041.38 |
| 预付款项 | 11,378,516.56 | 13,059,733.35 | 14,079,955.42 | 22,837,185.37 |
| 其他应收款合计 | 2,778,063.08 | 2,731,474.01 | 4,862,460.19 | 3,174,961.56 |
| 存货 | 102,397,398.38 | 102,418,450.82 | 107,253,297.36 | 80,953,188.46 |
| 合同资产 | 9,224,879.32 | 7,446,413.64 | 11,091,821.57 | 11,491,162.37 |
| 其他流动资产 | 60,780,066.96 | 13,609,284.63 | 8,788,010.09 | 7,400,017.9 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 983,289,086.99 | 976,317,889.19 | 1,001,124,515.31 | 945,125,169.97 |
| 非流动资产: | | | | |
| 长期股权投资 | 64,405,714.41 | 64,416,376.31 | 63,759,966.36 | 65,190,069.76 |
| 固定资产 | 295,362,470.83 | 263,565,659.95 | 247,962,967.87 | 249,198,018.42 |
| 在建工程 | 61,538,657.62 | 80,754,194.31 | 32,533,880.59 | 22,756,379.79 |
| 使用权资产 | 9,931.07 | 24,827.63 | 39,724.19 | 54,620.75 |
| 无形资产 | 19,954,595 | 21,650,482.01 | 22,508,845.51 | 24,163,542.85 |
| 商誉 | 18,385,750.74 | 18,385,750.74 | 18,385,750.74 | 18,385,750.74 |
| 长期待摊费用 | 814,239.19 | 918,295.28 | 882,974.62 | 1,026,110.76 |
| 递延所得税资产 | 18,958,796.01 | 19,330,308.72 | 17,622,417.22 | 16,237,253.11 |
| 其他非流动资产 | 5,944,503.06 | 7,940,309.06 | 24,652,498.27 | 19,216,052.34 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 485,374,657.93 | 476,986,204.01 | 428,349,025.37 | 416,227,798.52 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,468,663,744.92 | 1,453,304,093.2 | 1,429,473,540.68 | 1,361,352,968.49 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 27,611,574.16 | 20,667,815.65 | 21,751,426.17 | 18,342,633.61 |
| 应付账款 | 27,611,574.16 | 20,667,815.65 | 21,751,426.17 | 18,342,633.61 |
| 合同负债 | 37,821,685.35 | 30,440,121.14 | 42,656,632.18 | 35,854,403.74 |
| 应付职工薪酬 | 12,677,618.58 | 24,461,481.93 | 11,038,829.11 | 10,040,669.36 |
| 应交税费 | 7,318,260.49 | 8,881,873.55 | 8,709,191.55 | 2,942,850.97 |
| 其他应付款合计 | 13,325,292.89 | 16,503,119.26 | 26,782,865.79 | 12,760,832.75 |
| 应付股利 | 1,760,946.75 | 1,760,946.75 | 11,228,847.28 | - |
| 一年内到期的非流动负债 | 6,557.72 | 6,392.93 | 22,087.39 | 54,335.38 |
| 其他流动负债 | 2,261,503.76 | 2,225,845.46 | 1,411,356.36 | 818,665.13 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 101,022,492.95 | 103,186,649.92 | 112,372,388.55 | 80,814,390.94 |
| 非流动负债: | | | | |
| 递延收益 | 71,791,502.21 | 74,719,106.5 | 77,622,918.32 | 67,108,823.14 |
| 递延所得税负债 | 2,356,102.91 | 2,393,999.02 | 2,426,870.72 | 2,462,507.63 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 74,147,605.12 | 77,113,105.52 | 80,049,789.04 | 69,571,330.77 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 175,170,098.07 | 180,299,755.44 | 192,422,177.59 | 150,385,721.71 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 453,340,000 | 453,340,000 | 453,340,000 | 453,340,000 |
| 资本公积 | 513,570,870.69 | 513,570,870.69 | 512,869,911.23 | 512,870,241.86 |
| 减:库存股 | 36,126,025.26 | 36,126,025.26 | 36,126,025.26 | 35,005,569.17 |
| 其他综合收益 | - | - | -120,689.76 | -134,800.23 |
| 盈余公积 | 32,202,213.54 | 32,202,213.54 | 24,565,923.73 | 24,565,923.73 |
| 未分配利润 | 330,506,587.88 | 310,017,278.79 | 282,522,243.15 | 255,331,450.59 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,293,493,646.85 | 1,273,004,337.76 | 1,237,051,363.09 | 1,210,967,246.78 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,293,493,646.85 | 1,273,004,337.76 | 1,237,051,363.09 | 1,210,967,246.78 |
| 负债和股东权益合计 | 1,468,663,744.92 | 1,453,304,093.2 | 1,429,473,540.68 | 1,361,352,968.49 |
| 公告日期 | 2025-04-30 | 2025-04-30 | 2024-10-30 | 2024-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |